Formulating erythropoietin-loaded sustained-release PLGA microspheres without protein aggregation

Journal of Controlled Release

Volumn 130, Issue 3, 2008, Pages 259-265

  Geng, Yan ^a   Yuan, Weien ^a   Wu, Fei ^a   Chen, Jingle ^a   He, Mu ^a   Jin, Tuo ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Aggregation; Erythropoietin; Microspheres; Sustained release

Indexed keywords

ACIDS; BLOOD; DEXTRAN; DICHLOROMETHANE; DISSOLUTION; EMULSIFICATION; ETHYLENE GLYCOL; FREEZING; GLUCOSE; GLYCOLS; MICROSPHERES; ORGANIC COMPOUNDS; ORGANIC SOLVENTS; POLYETHYLENE GLYCOLS; POLYSACCHARIDES; SOLVENTS;

AGGREGATION; ERYTHROPOIETIN; PLGA MICROSPHERES; SUSTAINED-RELEASE;

PHASE INTERFACES;

DEXTRAN; DICHLOROMETHANE; ERYTHROPOIETIN; MACROGOL; MICROSPHERE; POLYGLACTIN; POLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; EMULSION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; FREEZE DRYING; MALE; MICROENCAPSULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; SUSTAINED DRUG RELEASE;

ANIMALS; ANTIBODY FORMATION; BIOLOGICAL AVAILABILITY; DELAYED-ACTION PREPARATIONS; DEXTRANS; ERYTHROCYTE COUNT; ERYTHROPOIESIS; ERYTHROPOIETIN, RECOMBINANT; HUMANS; LACTIC ACID; MALE; MICE; MICE, INBRED BALB C; MICROSPHERES; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; X-RAY DIFFRACTION;

EID: 50949096580     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.06.011     Document Type: Article

References (32)

1. Chen R.R., and Mooney D.J. Polymeric growth factor delivery strategies for tissue engineering. Pharm. Res. 20 8 (2003) 1103-1112
2. van de Weert M., Hennink W.E., and Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm. Res. 17 10 (2000) 1159-1167
3. Jin T., Zhu J., Wu F., Yuan W., and Geng L Z.H. Preparing polymer-based sustained-release systems without exposing protein to water-oil or water-air interface and cross-linking reagents. J. Control. Release 128 1 (2008) 50-59
4. Genc S., Koroglu T.F., and Genc K. Erythropoietin as a novel neuroprotectant. Restorative neurology and neuroscience 22 2 (2004) 105-119
5. Zhang D., Zhang F., Zhang Y., Gao X., Li C., Ma W., and Cao K. erythropoietin enhances the angiogenic potency of autologous bone marrow stromal cells in a rat model of myocardial infarction. Cardiology 108 4 (2006) 228-236
6. Westenbrink B.D., Voors A.A., Ruifrok W.P., van Gilst W.H., and van Veldhuisen D.J. Therapeutic potential of erythropoietin in cardiovascular disease: erythropoiesis and beyond. Current heart failure reports 4 3 (2007) 127-133
7. Schellekens H. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best practice & research 18 3 (2005) 473-480
8. Morlock M., Koll H., Winter G., and Kissel T. Microencapsulation of rh-erythropoietin, using biodegradable poly(dl,-lactide-co-glycolide): protein stability and the effects of stabilizing excipients. European Journal of Pharmaceutics and Biopharmaceutics 43 1 (1997) 29-36
9. Morlock M., Kissel T., Li Y.X., Koll H., and Winter G. Erythropoietin loaded microspheres prepared from biodegradable LPLG-PEO-LPLG triblock copolymers: protein stabilization and in-vitro release properties. J. Control. Release 56 1-3 (1998) 105-115
10. Commission E.P. European Pharmacopoeia (2001)
11. S.E. Zale, P.A. Burke, H. Bernstein, A. Brickner, Composition for sustained release of non-aggregated erythropoietin, U.S. Patent 5,716,644 (Feb 10, 1998).
12. Hahn S.K., Oh E.J., Miyamoto H., and Shimobouji T. Sustained release formulation of erythropoietin using hyaluronic acid hydrogels crosslinked by Michael addition. International journal of pharmaceutics 322 1-2 (2006) 44-51
13. Ito Y., Shiroyama K., Yoshimitsu J., Ohashi Y., Sugioka N., and Takada K. Pharmacokinetic and pharmacodynamic studies following percutaneous absorption of erythropoietin micropiles to rats. J. Control. Release 121 3 (2007) 176-180
14. Yuan W., Wu F., Geng Y., Xu S., and Jin T. Preparation of dextran glassy particles through freezing-induced phase separation. International journal of pharmaceutics 339 1-2 (2007) 76-83
15. Merril C.R., and Pratt M.E. A silver stain for the rapid quantitative detection of proteins or nucleic acids on membranes or thin layer plates. Analytical biochemistry 156 1 (1986) 96-110
16. Wray W., Boulikas T., Wray V.P., and Hancock R. Silver staining of proteins in polyacrylamide gels. Analytical biochemistry 118 1 (1981) 197-203
17. Urra J.M., de la Torre M., Alcazar R., and Peces R. Rapid method for detection of anti-recombinant human erythropoietin antibodies as a new form of erythropoietin resistance. Clinical chemistry 43 5 (1997) 848-849
18. Bondos S.E., and Bicknell A. Detection and prevention of protein aggregation before, during, and after purification. Analytical biochemistry 316 2 (2003) 223-231
19. Cleland J.L., and Jones J.S. Stable formulations of recombinant human growth hormone and interferon-gama for microencapsulation in biodegradable microspheres. Pharm. Res. 13 10 (1996) 1464-1475
20. Raymond C.P., Paul J.S., and Weller P.J. Handbook of Pharmaceutical Excipients (2003), Pharmaceutical Press and American Pharmaceutical Association
21. Glossary of Terms Relating to Powders (1958), British standards institution, London
22. Tracy M.A., Ward K.L., Firouzabadian L., Wang Y., Dong N., Qian R., and Zhang Y. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials 20 11 (1999) 1057-1062
23. Egrie J.C., Dwyer E., Browne J.K., Hitz A., and Lykos M.A. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Experimental hematology 31 4 (2003) 290-299
24. Breen E.D., Curley J.G., Overcashier D.E., Hsu C.C., and Shire S.J. Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation. Pharm. Res. 18 9 (2001) 1345-1353
25. Chang L.L., Shepherd D., Sun J., Tang X.C., and Pikal M.J. Effect of sorbitol and residual moisture on the stability of lyophilized antibodies: implications for the mechanism of protein stabilization in the solid state. Journal of pharmaceutical sciences 94 7 (2005) 1445-1455
26. Padhi D., Ni L., Cooke B., Marino R., and Jang G. An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clinical pharmacokinetics 45 5 (2006) 503-510
27. Haselbeck A., Bailon P., and Pahle W. The discovery and characterization of CERA, an innovative agent for the treatment of anemia. Blood 100 227A (2002) 857
28. Drueke T.B., Locatelli F., Clyne N., Eckardt K.U., Macdougall I.C., Tsakiris D., Burger H.U., and Scherhag A. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. The New England journal of medicine 355 20 (2006) 2071-2084
29. Christina A.S. Darbepoetin (Aranesp®) update. Pharmacy Newsletter 28 3 (2007) 1-2
30. Erythropoiesis Stimulating Agents (ESA) [Aranesp (darbepoetin),Epogen (epoetin alfa), and Procrit (epoetin alfa)]., U.S. Food and Drug Administration. Available at http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm. (2007).
31. Krzyzanski W., Jusko W.J., Wacholtz M.C., Minton N., and Cheung W.K. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur. J. Pharm. Sci. 26 3-4 (2005) 295-306
32. Duplay D. Physicians' Desk Reference (2005), Thomson PDR, Montvale